Marker Therapeutics
MRKR
5 hedge funds and large institutions have $75K invested in Marker Therapeutics in 2017 Q2 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, 0 reducing their positions, and 3 closing their positions.
0.02% less ownership
Funds ownership: 0.04% → 0.02% (-0.02%)
17% less funds holding
Funds holding: 6 → 5 (-1)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
54% less capital invested
Capital invested by funds: $163K → $75K (-$88K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$57.6K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$7.91K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VKH
Virtu KCG Holdings
New York
|
-$54K |
| 2 |
Millennium Management
New York
|
-$50K |
| 3 |
Goldman Sachs
New York
|
-$48K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
BlackRock
New York
| $57K | +$57.6K | +1,463 | New |
|
|
NSIM
2
North Star Investment Management
Chicago,
Illinois
| $9K | – | – | – |
|
|
3
UBS Group
Zurich,
Switzerland
| $8K | +$7.91K | +201 | New |
|
|
AG
4
Advisor Group
Phoenix,
Arizona
| $1K | – | – | – |
|
|
VKH
5
Virtu KCG Holdings
New York
| – | -$54K | -1,211 | Closed |
|
|
6
Millennium Management
New York
| – | -$50K | -1,103 | Closed |
|
|
7
Goldman Sachs
New York
| – | -$48K | -1,059 | Closed |
|
MRKR Hedge Fund Activity: Q2 2017 in Review
5 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Marker Therapeutics (MRKR) for Q2 2017, worth a combined $75K — down 54% from $163K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of MRKR and 2 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest buyer was BlackRock, opening a new position worth an estimated $57.6K. The largest seller was Virtu KCG Holdings, exiting entirely with an estimated $54K sold.
- 5 institutional investors held Marker Therapeutics (MRKR) as of Q2 2017, down from 6 in Q1 2017.
- Funds reported $75K of Marker Therapeutics stock for Q2 2017, down 54% quarter-over-quarter.
- 2 funds opened new Marker Therapeutics positions in Q2 2017 and 3 closed out, a net change of -1 holder.
- The largest Marker Therapeutics buyer in Q2 2017 was BlackRock, an estimated $57.6K added.
- The largest Marker Therapeutics seller in Q2 2017 was Virtu KCG Holdings, an estimated $54K sold.
Based on aggregated 13F filings for Q2 2017.